The treatment landscape for non-Hodgkin lymphoma has significantly evolved over the past few decades. With groundbreaking advancements in CAR T-cell therapy and bispecific antibodies, researchers are making strides toward curative treatments and enhancing patients’ quality of life.
In this episode, we speak with Dr. David Bond from The Ohio State University about the latest developments in treating both aggressive and slow-growing non-Hodgkin lymphomas. He discusses innovative, newly approved therapies for patients, as well as how improvements in supportive care better manage the physical and emotional side effects of treatment.
Podcast: Play in new window | Download
Subscribe: Spotify | Pandora | Blubrry | JioSaavn | Podchaser | More
CLICK HERE to participate in our episode survey.Mentioned on this episode:
- Non-Hodgkin lymphoma
- CAR T-cell Therapy
- Bispecific Antibodies – Immunotherapy Fact Sheet
- Mental Health Support
- Patti Robinson Kaufmann First Connection Program®
Additional LLS Support Resources:
- Information Specialists
- Free Nutrition Consultations
- Financial support
- Free telephone/web patient programs
- Free booklets
- Young Adult Resources
- Online chats
- LLS Community
- Clinical Trial Support Center
- Support groups
- Caregiver support
- Caregiver Workbook
- Advocacy and Public Policy
- Survivorship Workbook
Support for this episode is provided by Genentech, Inc.
The Bloodline podcast is a very convenient way to get medical updates from LLS! Thank you for establishing this new communication forum.
Thank you for this information.
I have non-Hodgkin lymphoma and
Appreciate the support.